A Multicenter, Dose Escalating Study in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma
Groups of 3-6 patients are sequentially assigned to receive escalating doses of SU5416 in
33% increments. Study drug is administered as a twice-weekly intravenous injection for 4
weeks. In the absence of unacceptable toxicity, responding patients may continue on SU5416
in 4-week treatment cycles for a maximum of 1 year or until the presence of unacceptable
toxicity or tumor progression.
Interventional
Endpoint Classification: Safety Study, Primary Purpose: Treatment
United States: Food and Drug Administration
294A
NCT00002226
Name | Location |
---|---|
New York Univ Med Ctr | New York, New York 10016 |
UCLA Care Ctr / Ctr for Hlth Sciences | Los Angeles, California 900951793 |
Norris Cancer Ctr / USC | Los Angeles, California 90033 |
Saint Francis Mem Hosp / HIV Care Unit | San Francisco, California 94109 |